Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma.

Eugster, Philippe J; Maurer, Jonathan; Vocat, Céline; Abid, Karim; Matter, Maurice; Wuerzner, Grégoire; Trepp, Roman; Fischli, Stefan; Henzen, Christoph; Kolb, Walter; Bilz, Stefan; Sigrist, Sarah; Beuschlein, Felix; Nölting, Svenja; Reul, Astrid; Schütze, Ina; Hubers, Scott A; Brown, Nancy J; Grouzmann, Eric (2022). Proneuropeptide Y and neuropeptide Y metabolites in healthy volunteers and patients with a pheochromocytoma or paraganglioma. Clinica chimica acta, 534, pp. 146-155. Elsevier 10.1016/j.cca.2022.07.018

Preview

Text 1-s2.0-S0009898122012499-main.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (1MB) | Preview

Neuropeptide Y (NPY1-36) is a vasoconstrictor peptide co-secreted with catecholamines by sympathetic nerves, the adrenal medulla, and neoplasms such as pheochromocytomas and paragangliomas (PPGLs). It is produced by the intracellular cleavage of proNPY and metabolized into multiple fragments with distinct biological activities. NPY immunoassays for PPGL have a diagnostic sensitivity ranging from 33-100%, depending on the antibody used. We have validated a multiplex micro-UHPLC-MS/MS assay for the specific and sensitive quantification of proNPY, NPY1-39, NPY1-37, NPY1-36, NPY2-36, NPY3-36, NPY1-35, NPY3-35, and the C-flanking peptide of NPY (CPON) (collectively termed NPYs), and determined the NPYs reference intervals and concentrations in 32 PPGL patients before, during, and after surgery. Depending on the peptide measured, NPYs were above the upper reference limit (URL) in 20% to 67% of patients, whereas plasma free metanephrine and normetanephrine, the gold standard for PPGL, were above the URL in 40% and 87% of patients, respectively. Age, sex, tachycardia, and tumor localization were not correlated with NPYs. Plasma free metanephrines performed better than NPYs in the detection of PPGL, but NPYs may be a substitute for an early diagnosis of PPGL for patients that suffer from severe kidney impairment or receiving treatments that interfere with catecholamine reuptake.

Interest & Impact

Downloads

60 since deposited on 02 Aug 2022
32 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item